Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
Open Access
- 22 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e76829
Abstract
A significant barrier to effective immune clearance of cancer is loss of antitumor cytotoxic T cell activity. Antibodies to block pro-apoptotic/downmodulatory signals to T cells are currently being tested. Because invariant natural killer T cells (iNKT) can regulate the balance of Th1/Th2 cellular immune responses, we characterized the frequencies of circulating iNKT cell subsets in 21 patients with melanoma who received the anti-CTLA4 monoclonal antibody tremelimumab alone and 8 patients who received the antibody in combination with MART-126–35 peptide-pulsed dendritic cells (MART-1/DC). Blood T cell phenotypes and functionality were characterized by flow cytometry before and after treatment. iNKT cells exhibited the central memory phenotype and showed polyfunctional cytokine production. In the combination treatment group, high frequencies of pro-inflammatory Th1 iNKT CD8+ cells correlated with positive clinical responses. These results indicate that iNKT cells play a critical role in regulating effective antitumor T cell activity.Keywords
This publication has 60 references indexed in Scilit:
- Preferential depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infectionMucosal Immunology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapyInternational Journal of Hematology, 2012
- Cancer immunotherapy comes of ageNature, 2011
- IL-17–producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expressionBlood, 2011
- Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancerClinical Immunology, 2011
- Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defectsClinical Immunology, 2011
- New ways to turn on NKT cellsJournal of Experimental Medicine, 2011
- Invariant natural killer T cells and immunotherapy of cancerClinical Immunology, 2008